Fennec Pharmaceuticals Inc logo

FRX - Fennec Pharmaceuticals Inc Share Price

C$12 0.5  4.4%

Last Trade - 07/08/20

Small Cap
Market Cap £175.0m
Enterprise Value £167.5m
Revenue £n/a
Position in Universe 437th / 2679
Unlock FRX Revenue
Relative Strength (%)
1m +2.44%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.37%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 26.4 68.8
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Fennec Pharmaceuticals Inc revenues was not reported. Net loss increased 18% to $8.7M. Higher net loss reflects General and administrative increase of 60% to $6.2M (expense), Interest income and other decrease of 70% to $52K (income), Amortization expense of Deferred Issuanc increase of 62% to $47K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.37 to -$0.40.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for FRX
Graphical History


FRX Revenue Unlock FRX Revenue

Net Income

FRX Net Income Unlock FRX Revenue

Normalised EPS

FRX Normalised EPS Unlock FRX Revenue

PE Ratio Range

FRX PE Ratio Range Unlock FRX Revenue

Dividend Yield Range

FRX Dividend Yield Range Unlock FRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
FRX EPS Forecasts Unlock FRX Revenue
Profile Summary

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated August 25, 2011
Public Since June 5, 2001
No. of Shareholders: n/a
No. of Employees: 1
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Toronto Stock Exchange
Shares in Issue 25,356,000
Free Float (0.0%)
Eligible for
FRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for FRX
Upcoming Events for FRX
Tuesday 10th November, 2020 Estimate
Q3 2020 Fennec Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Fennec Pharmaceuticals Inc
What is the Fennec Pharmaceuticals Inc share price?

As of 07/08/20, shares in Fennec Pharmaceuticals Inc are trading at C$12, giving the company a market capitalisation of £175.0m. This share price information is delayed by 15 minutes.

How has the Fennec Pharmaceuticals Inc share price performed this year?

Shares in Fennec Pharmaceuticals Inc are currently trading at C$12 and the price has moved by 92% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Fennec Pharmaceuticals Inc price has moved by 89.25% over the past year.

What are the analyst and broker recommendations for Fennec Pharmaceuticals Inc?

There are no analysts currently covering Fennec Pharmaceuticals Inc.

When will Fennec Pharmaceuticals Inc next release its financial results?

Fennec Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Fennec Pharmaceuticals Inc dividend yield?

Fennec Pharmaceuticals Inc does not currently pay a dividend.

Does Fennec Pharmaceuticals Inc pay a dividend?

Fennec Pharmaceuticals Inc does not currently pay a dividend.

When does Fennec Pharmaceuticals Inc next pay dividends?

Fennec Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Fennec Pharmaceuticals Inc shares?

To buy shares in Fennec Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Fennec Pharmaceuticals Inc?

Shares in Fennec Pharmaceuticals Inc are currently trading at C$12, giving the company a market capitalisation of £175.0m.

Where are Fennec Pharmaceuticals Inc shares listed? Where are Fennec Pharmaceuticals Inc shares listed?

Here are the trading details for Fennec Pharmaceuticals Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: FRX
What kind of share is Fennec Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Fennec Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Fennec Pharmaceuticals Inc share price forecast 2020?

Shares in Fennec Pharmaceuticals Inc are currently priced at C$12. At that level they are trading at 97.96% discount to the analyst consensus target price of 0.00.

Analysts covering Fennec Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.28 for the next financial year.

How can I tell whether the Fennec Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Fennec Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 47.26%. At the current price of C$12, shares in Fennec Pharmaceuticals Inc are trading at 39.55% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Fennec Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Fennec Pharmaceuticals Inc.

Who are the key directors of Fennec Pharmaceuticals Inc?

Fennec Pharmaceuticals Inc's management team is headed by:

Rostislav Raykov - CEO
Robert Andrade - CFO
Chris Rallis - IND
Steven Skolsky - IND
Khalid Islam - CHM
Adrian Haigh - IND
Marco Brughera - DRC
Shubh Goel - OTH
Jodi Cook - DRC
Who are the major shareholders of Fennec Pharmaceuticals Inc?

Here are the top five shareholders of Fennec Pharmaceuticals Inc based on the size of their shareholding:

Southpoint Capital Advisors LP Hedge Fund
Percentage owned: 16.08% (4.08m shares)
ESSETIFIN S.p.A. Corporation
Percentage owned: 15.75% (3.99m shares)
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 6.57% (1.67m shares)
Sonic Fund II, L.P. Investment Advisor
Percentage owned: 6.45% (1.63m shares)
Solas Capital Management, LLC Hedge Fund
Percentage owned: 3.79% (960k shares)
Similar to FRX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.